This claim runs counter to some recent data suggesting Evusheld is protective against Omicron and its subvariants. We will write to stakeholders with more information on the decision shortly,” a government spokesperson told Medscape UK. “Following a robust review of the available data, our clinical experts advise there is currently insufficient data on the duration of protection offered by Evusheld in relation to the Omicron variant and the government will not be procuring any doses at this time. The UK government currently is not purchasing AstraZeneca’s COVID-19 pre-exposure prophylaxis Evusheld based on concerns about the therapy’s efficacy against SARS-CoV-2 variants and subvariants, according to a report from BMJ UK government opts not to purchase COVID PrEP therapy Evusheld As more vaccines continue to be developed and approved, the JCVI will consider the benefits of including them in the UK programme,” Wei Shen Lim, chair of COVID-19 immunization on the committee, said in a statement. “All of the available booster vaccines offer very good protection against severe illness from COVID-19. JCVI said they would evaluate other bivalent COVID-19 vaccines if approved by MHRA.

The Medicines and Healthcare products Regulatory Agency (MHRA) recently approved the Moderna bivalent COVID-19 vaccine for use in adults (RELATED: UK MHRA is first to authorize Moderna’s bivalent COVID-19 booster, Regulatory Focus 12 August 2022). JCVI advised the UK government to adopt Pfizer’s Comirnaty and Moderna’s Spikevax for the autumn booster program in addition to Moderna’s bivalent COVID-19 vaccine for adults, with Novavax’s recently approved vaccine recommended “when no alternative clinically suitable UK-approved COVID-19 vaccine is available.” For adolescents, JCVI recommends Cormirnaty, while children between 6-11 years old should receive the pediatric formulation of Comirnaty, the committee said. The UK Joint Committee on Vaccination and Immunisation (JCVI) has recommended a mix of COVID-19 vaccines based on the original wild-type SARS-CoV-2 virus as well as Moderna’s bivalent COVID-19 vaccine that targets both the original virus and the B.1 Omicron variant for its autumn booster program.

Focus booster uk